Johnson & Johnson Announces Results from Phase 2b DUPLEX-AD Study
Originally Published 17 days ago — by Johnson & Johnson
Johnson & Johnson announced that their Phase 2b DUPLEX-AD study for JNJ-5939 in treating moderate to severe atopic dermatitis was terminated early after not meeting efficacy criteria, though the drug was well tolerated. The company remains committed to developing new treatments for the high-need condition.